Skip to main content

Eli Lilly and Company company profile

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.37T

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products within a single business segment. Its portfolio includes insulin analogs for diabetes, incretin-based medicines for type 2 diabetes and obesity, and oncology, immunology, and dermatology treatments. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, Europe, and Asia, and sells them in approximately 90 countries. Its customers include wholesale distributors, pharmacies, pharmacy benefit managers, insurers, hospitals, and government institutions. In the U.S., most products are distributed through wholesalers, and three of them each accounted for a significant share of consolidated revenue. The company also sells directly to patients through LillyDirect, a digital platform.

A summary of the business section of the company's latest annual report, filed 12 Feb 2026.

Company facts

TickerLLY · NYSE
SectorPharmaceuticals
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK59478
Latest annual report10-K, filed 12 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
David RicksPresident, Chair, and CEO · Director816K · < 1%Gift, 3 Nov 2026
Daniel Skovronsky, M.D., Ph.D.EVP, CS&amp;PO &amp; Pres. LRL236K · < 1%Gift, 2 Nov 2026
Anat HakimEVP, GC &amp; Secretary55.6K · < 1%Sale under a 10b5-1 plan, 2 Nov 2026
Lucas MontarceEVP &amp; CFO16.3K · < 1%Option exercise, 1 Nov 2026
J. Erik FyrwaldDirector1.7K · < 1%Grant or award, 19 Oct 2026
Ralph AlvarezDirector758 · < 1%Grant or award, 19 Oct 2026
Mary Lynne HedleyDirector346 · < 1%Grant or award, 15 Dec 2025
Jamere JacksonDirector200 · < 1%Grant or award, 17 Nov 2025
Gabrielle SulzbergerDirector117 · < 1%Grant or award, 19 Oct 2026
Juan LucianoDirector0 · < 1%Grant or award, 19 Oct 2026
Katherine Baicker, Ph.D.Director0 · < 1%Grant or award, 17 Nov 2025
Kimberly JohnsonDirector0 · < 1%Grant or award, 17 Nov 2025
William Kaelin, Jr., M.D.Director0 · < 1%Grant or award, 17 Nov 2025
Jonsson PatrikEVP &amp; President, LLY Int'l—Gift, 10 Nov 2026
Brown Adrienne SEVP, President LLY Imm—Option exercise, 1 Nov 2026
Custer Kenneth L.EVP &amp; President, Card Met Hlth—Option exercise, 1 Nov 2026
Dozier EricEVP, Chief People Officer—Option exercise, 1 Nov 2026
Hernandez EdgardoEVP &amp; Pres., Mfg. Operations—Option exercise, 1 Nov 2026
Seymour MelissaEVP, Global Quality—Gift, 9 Sep 2026
Zakrowski Donald ASVP, Finance, & CAO—Sale under a 10b5-1 plan, 10 Aug 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

LLY in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.